Efficacy of Gefitinib for Brain Metastasis of Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer Clinical Trial

Official title:

A Phase II Study of Gefitinib in Benefited Patients With Asymptomatic Brain Metastasis Advanced Non-Small Cell Lung Cancer by Chemotherapy

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT00614809
• Other study ID #: CSLC-0703
• Status: Active, not recruiting
• Phase: Phase 2
• First received: January 31, 2008
• Last updated: February 13, 2008
• Start date: December 2007
• Est. completion date: December 2010

Study information

• Verified date: December 2007
• Source: Guangdong Provincial People's Hospital
• Contact: n/a
• Is FDA regulated: No
• Health authority: China: Food and Drug AdministrationUnited States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

This is a non-randomized open-label uncontrolled phase II trial evaluating efficacy and toxicity of gefitinib in patients with asymptomatic advanced NSCLC who was benefitted by first line chemotherapy. Patients with stage IV NSCLC who have one or more asymptomatic brain metastasis who was benefitted by first line chemotherapy will receive oral gefitinib 250mg once daily until disease progression or unacceptable toxicity. These patients' direct DNA sequencing of tumor tissue EGFR exons 18-21 will be analyzed The response was evaluated by RECIST criteria after the patient received gefitinib 6 weeks.If the patients present with progress disease of brain metastasis after the therapy of gefitinib, the patients will receive irradiation of brain metastasis.If the response is stable disease,partial response or complete response,he will be examined by brain MRI every 12 weeks.

Description:

Inclusion criteria:

1. Histological or cytological documented stage IV NSCLC. Sputum cytology alone is excluded.

2. Extracerebral lesions show stable disease after first line chemotherapy. Patient has recovered from CTCAE grade 3/4 toxicity. Patients who had never received EGFR-TKI or EGFR monoclonal antibody.

3. Patients must be at least 18 years.

4. ECOG Performance Status 0, 1 or 2.

5. Life expectancy of at least 12 weeks.

6. Appraisable disease, the presence of at least three lesions if longest diameter <10 mm by brain MRI.

7. Haemoglobin ³ 10.0 g/dl, Absolute neutrophil count (ANC) ³1.5 x 109/L, platelets ³ 100 x 109/L.

8. Total bilirubin £ 1.5 x upper limit of normal (ULN)

9. ALT and AST < 2.5 x ULN in the absence of liver metastases, or < 5 x ULN in case of liver metastases.

10. Creatinine clearance ³ 60ml/min (calculated according to Cockcroft-gault formula).

11. PT-INR/PTT < 1.2 x ULN.

12. Written informed consent.

13. Able to comply with study and follow-up procedures.

Exclusion criteria:

1. Mixed small cell and non-small cell lung cancer histology.

2. Any unresolved toxicity>CTCAE grade 2 from previous anti-cancer therapy.

3. Patients with exposure to biotherapy, immunotherapy within 4 weeks of study entry.

4. Other concurrent anticancer therapy.

5. Patients with exposure to investigational drug therapy outside of this trial.

6. Lack of physical integrity of the upper gastrointestinal tract, or malabsorption syndrome, or inability to take oral medication, or have active peptic ulcer disease.

7. Any unstable systemic disease (including active infection, hepatic, renal, metabolic disease or seizure disorder requiring medication).

8. Significant cardiovascular event: congestive heart failure >NYHA class 2; unstable angina, active CAD (myocardial infarction more than 1 year prior to study entry is allowed); serious cardiac arrhythmia requiring anti-arrhythmic therapy ( beta blockers or digoxin are permitted) or uncontrolled hypertension.

9. Brain metastases or spinal cord compression, if treated before the start of study treatment, and have any symptoms. Symptoms include signs of increased intracranial pressure ,headache,nausea and vomiting,cognitive or affective disturbances,seizures,and focal neurologic symptoms.

10. History of another malignancy within the last 5 years except cured carcinoma in-situ of uterine cervix, cured basal cell carcinoma of skin and superficial bladder tumors [Ta, Tis & T1].

11. Pregnant or breast-feeding women.

12. Substance abuse, medical, psychological or social conditions that may interfere with the patient's participation in the study or evaluation of the study results.

13. Any condition that is unstable or could jeopardize the safety of the patient and their compliance in the study.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 45
• Est. completion date: December 2010
• Est. primary completion date: March 2010
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion criteria:

1. Histological or cytological documented stage IV NSCLC. Sputum cytology alone is excluded

2. Extracerebral lesions show stable disease after first line chemotherapy. Patient has recovered from CTCAE grade 3/4 toxicity. Patients who had never received EGFR-TKI or EGFR monoclonal antibody.

3. Patients must be at least 18 years.

4. ECOG Performance Status 0, 1 or 2.

5. Life expectancy of at least 12 weeks.

6. Appraisable disease, the presence of at least three lesions if longest diameter <10 mm by brain MRI.

7. Haemoglobin ³ 10.0 g/dl, Absolute neutrophil count (ANC) ³1.5 x 109/L, platelets ³ 100 x 109/L.

8. Total bilirubin £ 1.5 x upper limit of normal (ULN)

9. ALT and AST < 2.5 x ULN in the absence of liver metastases, or < 5 x ULN in case of liver metastases.

10. Creatinine clearance ³ 60ml/min (calculated according to Cockcroft-gault formula).11. PT-INR/PTT < 1.2 x ULN. 12. Written informed consent.13. Able to comply with study and follow-up procedures.

Exclusion criteria:

1. Mixed small cell and non-small cell lung cancer histology.

2. Any unresolved toxicity>CTCAE grade 2 from previous anti-cancer therapy.

3. Patients with exposure to biotherapy, immunotherapy within 4 weeks of study entry.

4. Other concurrent anticancer therapy.

5. Patients with exposure to investigational drug therapy outside of this trial.

6. Lack of physical integrity of the upper gastrointestinal tract, or malabsorption syndrome, or inability to take oral medication, or have active peptic ulcer disease.

7. Any unstable systemic disease (including active infection, hepatic, renal, metabolic disease or seizure disorder requiring medication).

8. Significant cardiovascular event: congestive heart failure >NYHA class 2; unstable angina, active CAD (myocardial infarction more than 1 year prior to study entry is allowed); serious cardiac arrhythmia requiring anti-arrhythmic therapy ( beta blockers or digoxin are permitted) or uncontrolled hypertension.

9. Brain metastases or spinal cord compression, if treated before the start of study treatment, and have any symptoms. Symptoms include signs of increased intracranial pressure ,headache,nausea and vomiting,cognitive or affective disturbances,seizures,and focal neurologic symptoms.

10. History of another malignancy within the last 5 years except cured carcinoma in-situ of uterine cervix, cured basal cell carcinoma of skin and superficial bladder tumors [Ta, Tis & T1].

11. Pregnant or breast-feeding women.

12. Substance abuse, medical, psychological or social conditions that may interfere with the patient's participation in the study or evaluation of the study results.

13. Any condition that is unstable or could jeopardize the safety of the patient and their compliance in the study.

Study Design

Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Brain Metastasis
• Brain Neoplasms
• Carcinoma, Non-Small-Cell Lung
• Lung Neoplasms
• Neoplasm Metastasis
• Non-Small Cell Lung Cancer

Intervention

Drug:
• gefitinib
gefitinib 250mg qd until disease progression or unacceptable toxicity.

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Guangdong Provincial People's Hospital

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Time of asymptomatic brain metastasis turn into symptomatic brain metastasis		12/2007~12/2010	No
Secondary	To determine objective response (CR+PR), time to progression, 6-month survival and 1-year survival,safety.		12/2007~12/2010	Yes